By what mechanisms do you think the GLP-1 RA liraglutide might have affected cardiovascular events, based on the finding of the LEADER trial?

By what mechanisms do you think the GLP-1 RA liraglutide might have affected cardiovascular events, based on the finding of the LEADER trial?

By what mechanisms do you think the GLP-1 RA liraglutide might have affected cardiovascular events, based on the finding of the LEADER trial?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

John Petrie, MD, PhD

John Petrie, MD, PhD

Professor of Diabetic Medicine
University of Glasgow
Honorary Consultant Physician and Diabetologist
Glasgow Royal Infirmary and Stobhill Hospital
Glasgow, Scotland